Predicted to enable phosphatidylinositol binding activity and type I transforming growth factor beta receptor binding activity. Predicted to be involved in negative regulation of pathway-restricted SMAD protein phosphorylation; negative regulation of transforming growth factor beta receptor signaling pathway; and receptor catabolic process. Predicted to be active in endosome. Orthologous to human SNX25 (sorting nexin 25). [provided by Alliance of Genome Resources, Apr 2022]